Opioid modulation of cognitive impairment in depression.

Abstract

The failure of traditional antidepressant medications to adequately target cognitive impairment is associated with poor treatment response, increased risk of relapse, and greater lifetime disability. Opioid receptor antagonists are currently under development as novel therapeutics for major depressive disorder (MDD) and other stress-related illnesses. Although it is known that dysregulation of the endogenous opioid system is observed in patients diagnosed with MDD, the impact of opioidergic neurotransmission on cognitive impairment has not been systematically evaluated. Here we review the literature indicating that opioid manipulations can alter cognitive functions in humans. Furthermore, we detail the preclinical studies that demonstrate the ability of mu-opioid receptor and kappa-opioid receptor ligands to modulate several cognitive processes. Specifically, this review focuses on domains within higher order cognitive processing, including attention and executive functioning, which can differentiate cognitive processes influenced by motivational state.

• Authors: Moriah L Jacobson, Hildegard A Wulf, Caroline A Browne, Irwin Lucki
• Journal: Progress in brain research (Prog Brain Res) Vol. 239 Pg. 1-48 ( 2018) ISSN: 1875-7855 [Electronic] Netherlands
• PMID: 30314565 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)
• Copyright: © 2018 Elsevier B.V. All rights reserved.

Chemical References

• Analgesics, Opioid
• Receptors, Opioid, mu

Topics

• Analgesics, Opioid (pharmacology, therapeutic use)
• Cognition (drug effects)
• Cognitive Dysfunction (drug therapy, etiology, metabolism)
• Depressive Disorder (complications, metabolism)
• Executive Function (drug effects)
• Humans
• Neuropsychological Tests
• Receptors, Opioid, mu (metabolism)